Real-World study checks Teclistamab's performance in Tough-to-Treat myeloma
NCT ID NCT06062537
First seen Apr 26, 2026 · Last updated May 14, 2026 · Updated 3 times
Summary
This study follows 200 adults with multiple myeloma that has come back or stopped responding to treatment. Researchers are tracking how well the drug teclistamab works and what side effects occur when used in everyday medical practice. The main goal is to see how many patients achieve at least a partial response to the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CH Bretagne Atlantique
Vannes, France
-
CH Dunkerque
Dunkirk, France
-
CH Perpignan
Perpignan, France
-
CH d'ANNECY
Annecy, France
-
CH de METZ
Metz, France
-
CHU Amiens Picardie
Amiens, France
-
CHU Bordeaux
Bordeaux, 31400, France
-
CHU CAEN
Caen, France
-
CHU Clermont-Ferrand Site Estaing
Clermont-Ferrand, France
-
CHU Henri Mondor
Créteil, France
-
CHU Saint-Eloi - CHU de Montpellier
Montpellier, France
-
CHU Toulouse
Toulouse, France
-
CHU de Besançon
Besançon, France
-
CHU de Lille
Lille, France
-
CHU de Nice
Nice, France
-
CHU de Tours
Tours, France
-
Centre Henri Becquerel
Rouen, France
-
Centre hospitalier Métropole de Savoie
Chambéry, France
-
Centre hospitalier d'Argenteuil
Argenteuil, France
-
Centre hospitalier de Brive-la-Gaillarde
Brive-la-Gaillarde, France
-
Chu Dijon
Dijon, France
-
Chu de Nantes
Nantes, France
-
Chu de Rennes
Rennes, France
-
Groupe hospitalier Bretagne Sud
Lorient, France
-
Hopital Necker
Paris, France
-
Hopital Novo
Pontoise, France
-
Hopital de Hautepierre
Strasbourg, France
-
Hopital de la cote Basque
Bayonne, France
-
Hopital saint louis
Paris, France
-
Institut Paoli Calmette
Marseille, France
-
Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne
Saint-Priest-en-Jarez, France
Conditions
Explore the condition pages connected to this study.